Cargando…
Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
SIMPLE SUMMARY: The PD-L1 22C3 and SP263 assays are routinely used to select patients for immunotherapy in NSCLC, and their IHC expression results demonstrate a strong correlation. However, their interchangeability should be carefully examined when using long-term preserved FFPE blocks more than 3 y...
Autores principales: | Kim, Sue Youn, Kim, Tae-Eun, Park, Chan Kwon, Yoon, Hyoung-Kyu, Sa, Young Jo, Kim, Hyo Rim, Woo, In Sook, Kim, Tae-Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265108/ https://www.ncbi.nlm.nih.gov/pubmed/35804910 http://dx.doi.org/10.3390/cancers14133138 |
Ejemplares similares
-
PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
por: Lee, Jongmin, et al.
Publicado: (2018) -
CT‐guided transthoracic needle biopsy for evaluation of PD‐L1 expression: Comparison of 22C3 and SP263 assays
por: Beck, Kyongmin S., et al.
Publicado: (2019) -
PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021) -
External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different
por: Dodson, Andrew, et al.
Publicado: (2019) -
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
por: Park, Yujun, et al.
Publicado: (2020)